SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Sjoholm F)
 

Sökning: WFRF:(Sjoholm F) > Effects of glucagon...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003861naa a2200409 4500
001oai:lup.lub.lu.se:00af0c4d-4158-46d9-afb0-ef363eea4ef9
003SwePub
008160401s2004 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:1939343
024a https://lup.lub.lu.se/record/2625852 URI
024a https://doi.org/10.1152/ajpendo.00237.20042 DOI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:19393432 URI
040 a (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Nystrom, Tu Karolinska Institutet4 aut
2451 0a Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
264 1b American Physiological Society,c 2004
520 a GLP-1 stimulates insulin secretion, suppresses glucagon secretion, delays gastric emptying, and inhibits small bowel motility, all actions contributing to the anti-diabetogenic peptide effect. Endothelial dysfunction is strongly associated with insulin resistance and type 2 diabetes mellitus and may cause the angiopathy typifying this debilitating disease. Therefore, interventions affecting both endothelial dysfunction and insulin resistance may prove useful in improving survival in type 2 diabetes patients. We investigated GLP-1's effect on endothelial function and insulin sensitivity (S-I) in two groups: 1) 12 type 2 diabetes patients with stable coronary artery disease and 2) 10 healthy subjects with normal endothelial function and S-I. Subjects underwent infusion of recombinant GLP-1 or saline in a random crossover study. Endothelial function was measured by postischemic FMD of brachial artery, using ultrasonography. S-I [in (10(-4) dl.kg(-1).min(-1))/(muU/ml)] was measured by hyperinsulinemic isoglycemic clamp technique. In type 2 diabetic subjects, GLP-1 infusion significantly increased relative changes in brachial artery diameter from baseline FMD(%) (3.1 +/- 0.6 vs. 6.6 +/- 1.0%, P < 0.05), with no significant effects on S-I (4.5 &PLUSMN; 0.8 vs. 5.2 &PLUSMN; 0.9, P = NS). In healthy subjects, GLP-1 infusion affected neither FMD(%) (11.9 &PLUSMN; 0.9 vs. 10.3 &PLUSMN; 1.0%, P = NS) nor S-I (14.8 &PLUSMN; 1.8 vs. 11.6 &PLUSMN; 2.0, P = NS). We conclude that GLP-1 improves endothelial dysfunction but not insulin resistance in type 2 diabetic patients with coronary heart disease. This beneficial vascular effect of GLP-1 adds yet another salutary property of the peptide useful in diabetes treatment.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Fysiologi0 (SwePub)301062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Physiology0 (SwePub)301062 hsv//eng
653 a nitric oxide
653 a insulin resistance
700a Gutniak, MK4 aut
700a Zhang, QMu Karolinska Institutet4 aut
700a Zhang, Fu Karolinska Institutet4 aut
700a Holst, JJ4 aut
700a Ahrén, Bou Lund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-bah
700a Sjoholm, Au Karolinska Institutet4 aut
710a Karolinska Institutetb Medicin, Lund4 org
773t American Journal of Physiology: Endocrinology and Metabolismd : American Physiological Societyg 287:6, s. 1209-1215q 287:6<1209-1215x 1522-1555x 0193-1849
856u http://dx.doi.org/10.1152/ajpendo.00237.2004x freey FULLTEXT
8564 8u https://lup.lub.lu.se/record/262585
8564 8u https://doi.org/10.1152/ajpendo.00237.2004
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:1939343

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy